What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to officially report Eli Lilly's financial results and operational performance for the second quarter ended June 30, 2020, through an attached press release.

Where can I find the detailed financial results?

The detailed financial results are provided in Exhibit 99.1, which is a press release dated July 30, 2020, attached to the 8-K filing.

Is the information in this filing legally binding in the same way as other filings?

The information in Item 2.02 of this 8-K, including the attached press release, is being furnished and is generally not deemed 'filed' for purposes of Section 18 of the Exchange Act. This means it may not be subject to the same level of legal liability as information in other types of SEC filings, although it still provides important disclosure to investors.

What kind of information should I expect in the press release?

You should expect unaudited financial results for the quarter, including revenue, earnings per share, and potentially commentary on key products, pipeline updates, and any forward-looking guidance or outlook provided by the company.

LLY 8-K: Earnings & Results

Summary

Eli Lilly and Company (LLY) filed an 8-K on July 30, 2020, to report its financial results for the quarter ended June 30, 2020. The filing primarily consists of a press release (Exhibit 99.1) detailing the company's operational performance and financial condition for the reported period. This announcement provides investors with key updates on revenue, earnings, and other financial metrics, offering insight into the company's performance amidst the evolving market landscape. Investors should pay close attention to the specific financial figures and any forward-looking statements or guidance provided within the press release. This information is crucial for understanding Lilly's current financial health, the impact of its product portfolio, and its strategic direction. The filing serves as a primary source for understanding Lilly's most recent financial performance.

Key Highlights

1The 8-K filing on July 30, 2020, announced Eli Lilly's financial results for the second quarter ended June 30, 2020.
2The primary content of the filing is a press release (Exhibit 99.1) detailing the company's operating results and financial condition.
3The press release provides unaudited financial information for the quarter.
4This filing serves as an official communication channel for the company's quarterly performance update to investors and the market.
5The information is furnished and not deemed 'filed' for certain sections of the Securities Exchange Act of 1934, which is standard for earnings releases.
6Key financial metrics, product performance, and potentially future outlook would be detailed within the attached press release.

ELI LILLY & Co 8-K Report, Financial Results (Jul 30, 2020)

Summary

Key Highlights

Frequently Asked Questions